User:Gurdeep
From DrugPedia: A Wikipedia for Drug discovery
(→Personal) |
(→Personal) |
||
| Line 5: | Line 5: | ||
== Personal == | == Personal == | ||
| - | Gurdeep Singh belongs to city beautiful | + | Gurdeep Singh belongs to city beautiful Chandigarh. |
| - | He has done his graduation and post-graduation in Microbiology, from Panjab University, Chandigarh. | + | He has done his graduation and post-graduation in Microbiology, from Panjab University, Chandigarh. Then he worked as JRF in the ICMR project titled “Study of association of Guillian-Barre Syndrome with Campylobacter infections” at Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh. After that he joined IMTECH (Institute of Microbial Technology) as a Project Assistant. Currently he is working as Junior Research Fellow in the field of Biochemical and Bioinformatics under the supervision Dr. D.K. Sahoo and Dr. GPS Raghava at the IMTECH. |
| - | Currently he is working as Junior Research Fellow in the field of Biochemical and Bioinformatics under the supervision Dr. D.K. Sahoo and Dr. GPS Raghava at the | + | |
== Area of Interest == | == Area of Interest == | ||
Revision as of 06:51, 18 September 2010
Gurdeep Singh
Gurdeep Singh is a Research Scholar at Institute of Microbial Technology (IMTECH), Chandigarh, India.
Personal
Gurdeep Singh belongs to city beautiful Chandigarh. He has done his graduation and post-graduation in Microbiology, from Panjab University, Chandigarh. Then he worked as JRF in the ICMR project titled “Study of association of Guillian-Barre Syndrome with Campylobacter infections” at Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh. After that he joined IMTECH (Institute of Microbial Technology) as a Project Assistant. Currently he is working as Junior Research Fellow in the field of Biochemical and Bioinformatics under the supervision Dr. D.K. Sahoo and Dr. GPS Raghava at the IMTECH.
Area of Interest
- In-silico approaches for reducing immunogenicity and aggregation properties of therapeutic proteins.
- Its validation through ex-vivo/in-vivo studies.
- Then bioprocessing of validated outcomes.
